quinolinic acid has been researched along with Cognitive Dysfunction in 10 studies
Quinolinic Acid: A metabolite of tryptophan with a possible role in neurodegenerative disorders. Elevated CSF levels of quinolinic acid are correlated with the severity of neuropsychological deficits in patients who have AIDS.
pyridinedicarboxylic acid : Any member of the class of pyridines carrying two carboxy groups.
quinolinic acid : A pyridinedicarboxylic acid that is pyridine substituted by carboxy groups at positions 2 and 3. It is a metabolite of tryptophan.
Cognitive Dysfunction: Diminished or impaired mental and/or intellectual function.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 8.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 8.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 7.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Low-grade inflammation is common in obesity, but the mechanism between inflammation and cognitive impairment in obesity is unclear." | 5.91 | Butyrate ameliorates quinolinic acid-induced cognitive decline in obesity models. ( Fang, X; Ge, X; Geng, D; Guan, L; Hu, M; Huang, XF; Liu, S; Pan, W; Tang, R; Wang, L; Xie, Y; Yu, Y; Zhang, J; Zheng, K; Zheng, M; Zheng, P; Zhou, L; Zhou, M, 2023) |
| " Type I and II interferons (IFNs) stimulate the KYN/TRP pathway, producing elevated QA/kynurenic acid (KA), a potential neurotoxic imbalance that may contribute to SLE-mediated cognitive dysfunction." | 4.12 | Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE. ( Anderson, EW; Aranow, C; Arazi, A; Diamond, B; Furie, RA; Goodwin, S; Jin, Y; Mackay, M; Roeser, J; Shih, A; Volpe, B, 2022) |
| "Tryptophan and its catabolites (TRYCATs) have been suggested to link peripheral immune system activation and central neurotransmitter abnormalities with relevance to the etio-pathophysiology of schizophrenia (SZ) and major depressive disorder (MDD)." | 4.02 | Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder. ( Cathomas, F; Guetter, K; Kaiser, S; Klaus, F; Seifritz, E, 2021) |
| "Increased accumulation of endogenous neurotoxin quinolinic acid has been found in various neurodegenerative diseases." | 3.88 | Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment. ( Loganathan, C; Thayumanavan, P, 2018) |
| "Several studies suggest a pathophysiologically relevant association between increased brain levels of the neuroinhibitory tryptophan metabolite kynurenic acid and cognitive dysfunctions in people with schizophrenia." | 3.88 | Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia. ( Beggiato, S; Giorgini, F; Notarangelo, FM; Sathyasaikumar, KV; Schwarcz, R, 2018) |
| "Low-grade inflammation is common in obesity, but the mechanism between inflammation and cognitive impairment in obesity is unclear." | 1.91 | Butyrate ameliorates quinolinic acid-induced cognitive decline in obesity models. ( Fang, X; Ge, X; Geng, D; Guan, L; Hu, M; Huang, XF; Liu, S; Pan, W; Tang, R; Wang, L; Xie, Y; Yu, Y; Zhang, J; Zheng, K; Zheng, M; Zheng, P; Zhou, L; Zhou, M, 2023) |
| "Strokes are becoming less severe due to increased numbers of intensive care units and improved treatments." | 1.62 | Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline. ( Callebert, J; Chabriat, H; Cogo, A; Huberfeld, G; Kubis, N; Launay, JM; Maïer, B; Mangin, G; Mazighi, M, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 5 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Anderson, EW | 4 |
| Fishbein, J | 1 |
| Hong, J | 1 |
| Roeser, J | 4 |
| Furie, RA | 4 |
| Aranow, C | 4 |
| Volpe, BT | 1 |
| Diamond, B | 4 |
| Mackay, M | 4 |
| Jin, Y | 3 |
| Shih, A | 3 |
| Arazi, A | 3 |
| Goodwin, S | 3 |
| Volpe, B | 3 |
| Ge, X | 1 |
| Zheng, M | 1 |
| Hu, M | 1 |
| Fang, X | 1 |
| Geng, D | 1 |
| Liu, S | 1 |
| Wang, L | 1 |
| Zhang, J | 1 |
| Guan, L | 1 |
| Zheng, P | 1 |
| Xie, Y | 1 |
| Pan, W | 1 |
| Zhou, M | 1 |
| Zhou, L | 1 |
| Tang, R | 1 |
| Zheng, K | 1 |
| Yu, Y | 1 |
| Huang, XF | 1 |
| Cogo, A | 1 |
| Mangin, G | 1 |
| Maïer, B | 1 |
| Callebert, J | 1 |
| Mazighi, M | 1 |
| Chabriat, H | 1 |
| Launay, JM | 1 |
| Huberfeld, G | 1 |
| Kubis, N | 1 |
| Cathomas, F | 1 |
| Guetter, K | 1 |
| Seifritz, E | 1 |
| Klaus, F | 1 |
| Kaiser, S | 1 |
| Loganathan, C | 1 |
| Thayumanavan, P | 1 |
| Sharma, R | 1 |
| Razdan, K | 1 |
| Bansal, Y | 1 |
| Kuhad, A | 1 |
| Beggiato, S | 1 |
| Notarangelo, FM | 1 |
| Sathyasaikumar, KV | 1 |
| Giorgini, F | 1 |
| Schwarcz, R | 1 |
| Lavisse, S | 1 |
| Williams, S | 1 |
| Lecourtois, S | 1 |
| van Camp, N | 1 |
| Guillermier, M | 1 |
| Gipchtein, P | 1 |
| Jan, C | 1 |
| Goutal, S | 1 |
| Eymin, L | 1 |
| Valette, J | 1 |
| Delzescaux, T | 1 |
| Perrier, AL | 1 |
| Hantraye, P | 1 |
| Aron Badin, R | 1 |
| Liu, P | 1 |
| Li, Y | 1 |
| Qi, X | 1 |
| Xu, J | 1 |
| Liu, D | 1 |
| Ji, X | 1 |
| Chi, T | 1 |
| Liu, H | 1 |
| Zou, L | 1 |
1 review available for quinolinic acid and Cognitive Dysfunction
| Article | Year |
|---|---|
Rollercoaster ride of kynurenines: steering the wheel towards neuroprotection in Alzheimer's disease.
Topics: Alzheimer Disease; Animals; Cognitive Dysfunction; Drug Development; Humans; Kynurenic Acid; Kynuren | 2018 |
9 other studies available for quinolinic acid and Cognitive Dysfunction
| Article | Year |
|---|---|
Quinolinic acid, a kynurenine/tryptophan pathway metabolite, associates with impaired cognitive test performance in systemic lupus erythematosus.
Topics: Cognitive Dysfunction; Cross-Sectional Studies; Humans; Kynurenine; Lupus Erythematosus, Systemic; N | 2021 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE.
Topics: Cognitive Dysfunction; Humans; Interferons; Kynurenic Acid; Kynurenine; Lupus Erythematosus, Systemi | 2022 |
Butyrate ameliorates quinolinic acid-induced cognitive decline in obesity models.
Topics: Animals; Brain-Derived Neurotrophic Factor; Butyrates; Cognitive Dysfunction; Humans; Inflammation; | 2023 |
Increased serum QUIN/KYNA is a reliable biomarker of post-stroke cognitive decline.
Topics: Animals; Biomarkers; Brain; Brain Ischemia; Cognitive Dysfunction; Diabetes Mellitus, Experimental; | 2021 |
Quinolinic acid is associated with cognitive deficits in schizophrenia but not major depressive disorder.
Topics: Adult; Case-Control Studies; Cognition; Cognitive Dysfunction; Depressive Disorder, Major; Female; H | 2021 |
Asiatic acid prevents the quinolinic acid-induced oxidative stress and cognitive impairment.
Topics: Animals; Antioxidants; Cognition; Cognitive Dysfunction; Lipid Peroxidation; Male; Neurodegenerative | 2018 |
Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Topics: Animals; Brain; Cognitive Dysfunction; Female; Genotype; Kynurenic Acid; Kynurenine; Kynurenine 3-Mo | 2018 |
Longitudinal characterization of cognitive and motor deficits in an excitotoxic lesion model of striatal dysfunction in non-human primates.
Topics: Animals; Cognitive Dysfunction; Corpus Striatum; Disease Models, Animal; Huntington Disease; Longitu | 2019 |
Protein kinase C is involved in the neuroprotective effect of berberine against intrastriatal injection of quinolinic acid-induced biochemical alteration in mice.
Topics: Animals; Berberine; Cognitive Dysfunction; Disease Models, Animal; Glutamic Acid; Glycogen Synthase | 2019 |